DUBLIN–(BUSINESS WIRE)–The “Brutons Tyrosine Kinase (BTK) Inhibitors – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Brutons Tyrosine Kinase (BTK) Inhibitors – Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
A detailed picture of the Brutons Tyrosine Kinase (BTK) Inhibitors pipeline landscape is provided which includes the disease overview and Brutons Tyrosine Kinase (BTK) Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Brutons Tyrosine Kinase (BTK) Inhibitors commercial assessment and clinical assessment of the pipeline products under development
. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Brutons Tyrosine Kinase (BTK) Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Brutons Tyrosine Kinase (BTK) Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Brutons Tyrosine Kinase (BTK) Inhibitors.
Brutons Tyrosine Kinase (BTK) Inhibitors Emerging Drugs Chapters
This segment of the Brutons Tyrosine Kinase (BTK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Brutons Tyrosine Kinase (BTK) Inhibitors Emerging Drugs
Zanubrutinib: BeiGene
Zanubrutinib (BGB-3111), a small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies. It is approved for the treatment of mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenstrom’s macroglobulinemia. In May 2021, BeiGene announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) for BRUKINSA (zanubrutinib) for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy and granted priority review.
Rilzabrutinib: Principia Biopharma
Rilzabrutinib (formerly known as PRN1008) is a BTK inhibitor, oral, first in class, wholly owned by Principia Biopharma is currently being evaluated in three different disease indications. It is currently in Phase III for Pemphigus, Immune Thrombocytopenia (ITP) and Phase II for autoimmune diseases like IgG4-Related Disease. Orphan drug designation is received from the United States Food and Drug Administration for rilzabrutinib for the treatment of pemphigus vulgaris and from the European Commission for the treatment of pemphigus (pemphigus vulgaris and pemphigus foliaceus).
Brutons Tyrosine Kinase (BTK) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Brutons Tyrosine Kinase (BTK) Inhibitors drugs segregated based on following parameters that define the scope of the report.
Major Players in Brutons Tyrosine Kinase (BTK) Inhibitors
There are approx. 30+ key companies which are developing the therapies for Brutons Tyrosine Kinase (BTK) Inhibitors. The companies which have their Brutons Tyrosine Kinase (BTK) Inhibitors drug candidates in the most advanced stage, i.e. Pre-registration include, BeiGene.
Key Players
- InnoCare Pharma
- BeiGene
- Principia Biopharma
- Carna Biosciences
- Loxo Oncology
- Aptose Biosciences
- Biogen
Key Products
- Orelabrutinib
- Zanubrutinib
- PRN473
- Rilzabrutinib
- AS-0871
- AS-1763
- Pirtobrutinib
- CG-806
- BIIB091
Key Topics Covered:
Introduction
Executive Summary
Brutons Tyrosine Kinase (BTK) Inhibitors: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
Rilzabrutinib: Principia Biopharma
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Orelabrutinib: InnoCare Pharma
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
PRN473: Principia Biopharma
- Product Description
- Research and Development
- Product Development Activities
Preclinical stage products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Brutons Tyrosine Kinase (BTK) Inhibitors Key Companies
Brutons Tyrosine Kinase (BTK) Inhibitors Key Products
Brutons Tyrosine Kinase (BTK) Inhibitors- Unmet Needs
Brutons Tyrosine Kinase (BTK) Inhibitors- Market Drivers and Barriers
Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/vwbbb5
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900